Asset Details
Do you wish to reserve the book?
Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia
Do you wish to request the book?
Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia
2021
Overview
Adverse genetic risk acute myeloid leukemia (AML) includes a wide range of clinical-pathological entities with extremely poor outcomes; thus, novel therapeutic approaches are needed. Promising results achieved by engineered chimeric antigen receptor (CAR) T cells in other blood neoplasms have paved the way for the development of immune cell-based therapies for adverse genetic risk AML. Among these, adoptive cell immunotherapies with single/multiple CAR-T cells, CAR-natural killer (NK) cells, cytokine-induced killer cells (CIK), and NK cells are subjects of ongoing clinical trials. On the other hand, allogeneic hematopoietic stem cell transplantation (allo-HSCT) still represents the only curative option for adverse genetic risk AML patients. Unfortunately, high relapse rates (above 50%) and associated dismal outcomes (reported survival ~10–20%) even question the role of current allo-HSCT protocols and emphasize the urgency of adopting novel effective transplant strategies. We have recently demonstrated that haploidentical allo-HSCT combined with regulatory and conventional T cells adoptive immunotherapy (Treg-Tcon haplo-HSCT) is able to overcome disease-intrinsic chemoresistance, prevent leukemia-relapse, and improve survival of adverse genetic risk AML patients. In this Perspective , we briefly review the recent advancements with immune cell-based strategies against adverse genetic risk AML and discuss how such approaches could favorably impact on patients’ outcomes.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Antigens
/ Biomarkers, Tumor - genetics
/ CAR-T
/ Cells
/ Cytokine-Induced Killer Cells - immunology
/ Cytokine-Induced Killer Cells - transplantation
/ Genetic Predisposition to Disease
/ HR-AML
/ HSCT
/ Humans
/ Immunotherapy, Adoptive - adverse effects
/ Immunotherapy, Adoptive - mortality
/ Killer Cells, Natural - immunology
/ Killer Cells, Natural - transplantation
/ Leukemia
/ Leukemia, Myeloid, Acute - genetics
/ Leukemia, Myeloid, Acute - immunology
/ Leukemia, Myeloid, Acute - mortality
/ Leukemia, Myeloid, Acute - therapy
/ Mutation
/ Patients
/ Receptors, Chimeric Antigen - genetics
/ T-Lymphocytes - transplantation
/ Tumors
